The trajectory of Sildenafil presents a complex case for observers in the medicinal sector. While initially a tremendous success, creating billions, the exclusivity lapse and the subsequent flood of generic versions have drastically impacted income. This presents questions about the ongoing profitability of similar therapeutic innovations and su… Read More